Pharmaceuticals News and Research

RSS

First Edition: May 6, 2014

Today's headlines include news from Massachusetts that the state is scrapping efforts to fix its troubled health exchange and will start over -- from scratch.

6 May 2014

Akorn’s consolidated revenue increases $90.6M to 23% in first quarter 2014

Akorn, Inc., a niche generic pharmaceutical company, today reported financial results for the first quarter ended March 31, 2014.

6 May 2014

Bayer to purchase consumer care business of Merck & Co, signs co-development deal for sGC modulators

Bayer has agreed to acquire the consumer care business of U.S. pharmaceutical company Merck & Co., Inc., Whitehouse Station, NJ, USA, for a purchase price of USD 14.2 billion (EUR 10.4 billion).

6 May 2014

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Novartis today presented results from a pivotal Phase III trial of investigational therapy Signifor® LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of care provides inadequate disease control.

6 May 2014

Macrogenics, CMC Biologics sign agreement to develop oncology product candidate

CMC Biologics, Inc., a global leader in process development and contract manufacturing, and MacroGenics, Inc. , a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases, have entered into an agreement to further develop the production process for transfer and clinical manufacturing of one of MacroGenics' product candidates.

6 May 2014

Debiopharm signs new license and research agreement with Yale University

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, announced it has signed a new license and research agreement with Yale University (Yale), a premier university with a long tradition of basic and clinical biomedical research, regarding the discovery of MIF inhibitors for treatment of autoimmune and inflammatory diseases.

6 May 2014

Kinex receives FDA allowance for Oratecan anti-cancer drug irinotecan with enhanced oral absorption

Kinex Pharmaceuticals, Inc. announced today that the United States Food and Drug Administration (FDA) has allowed its Investigational New Drug (IND) application for Oratecan, an oral form of an approved anti-cancer drug irinotecan with enhanced oral absorption.

6 May 2014

Attorney of Colson Hicks Eidson files wrongful death complaint on behalf of passenger killed on Macarthur Causeway

Attorney Ervin A. Gonzalez, partner at the Coral Gables-based law firm Colson Hicks Eidson, filed a wrongful death complaint in the 11th Judicial Circuit Court in Miami-Dade County on behalf of the family of the late Dr. Malcolm Lloyd, passenger in the Lamborghini that was involved in a fatal car crash on April 24th on MacArthur Causeway.

6 May 2014

Teva's SYNRIBO for injection receives FDA approval for home administration

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved SYNRIBO® (omacetaxine mepesuccinate) for injection, for subcutaneous use, to include home administration, and also approved a related Medication Guide and Instructions for Use.

6 May 2014

FDA approves Alexion’s Soliris drug for treatment of atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental Biologics License Application (sBLA) providing regular approval for Soliris® (eculizumab) for the treatment of adult and pediatric patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).

6 May 2014

BeiGene receives $5M from Merck to develop BGB-283 BRAF inhibitor

BeiGene (Beijing), Co., Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced the achievement of a clinical milestone in the company's collaboration with Merck Serono, the biopharmaceutical division of Merck, Darmstadt, Germany, for BGB-283, a second-generation BRAF inhibitor candidate currently in Phase 1 development.

6 May 2014

ERYTECH Pharma gets authorization to initiate Phase II study in pancreatic cancer

ERYTECH Pharma, a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces that the ANSM, French healthcare agency, has granted the authorization to start a Phase II study in second line treatment of patients affected by pancreatic cancer.

6 May 2014

Compounds in soy sauce can be 70 times more potent than first-line HIV drug Tenofovir

For HIV patients being treated with anti-AIDS medications, resistance to drug therapy regimens is commonplace. Often, patients develop resistance to first-line drug therapies, such as Tenofovir, and are forced to adopt more potent medications.

6 May 2014

Viewpoints: Learning from enrollment numbers; health costs soaring; value of vaccinations

Admit it: After seven months of full-blown hysteria, you're finding it hard to stay interested in how many people sign up for Obamacare. We've known for some time that whatever existential threats the Affordable Care Act faces, low enrollment is no longer one of them.

5 May 2014

Researchers analyze living cells quickly and accurately using Raman spectroscopy

In order to investigate inflammation, tumors or stem cells, medical practitioners analyze living cells. Non-invasive optical procedures such as Raman spectroscopy accelerate this procedure. Researchers have now developed it to industrial scale.

5 May 2014

Cigna profits are up but costs from early marketplace customers also higher than expected

The insurer also said "effective medical management" in its employer plans and Medicare Advantage business was helping rein in expenses, The Wall Street Journal reports.

5 May 2014

Trends, opportunities and threats in the life science industry: an interview with Bob Coughlin, CEO, MassBio

We were extremely excited to launch the Impact 2020 report at our annual meeting. Our five-year strategic plan is focused on value, early-stage financing and ensuring more patient-centered discussions.

5 May 2014

Cambrex sales decrease by 11.2% in first quarter 2014

Cambrex Corporation reports results for the first quarter ended March 31, 2014.

2 May 2014

Ruthigen files IND Application to FDA for lead drug candidate RUT58-60

Ruthigen, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics designed to prevent and treat infection in invasive applications, today announced that the Company has submitted an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration for its lead drug candidate RUT58-60.

2 May 2014

Isis Pharmaceuticals reports final data from ISIS-APOCIIIRx Phase 2 study in patients with FCS

Isis Pharmaceuticals, Inc. announced the final data from its Phase 2 study of ISIS-APOCIIIRx as a monotherapy in patients with familial chylomicronemia syndrome, or FCS.

2 May 2014

Pharmaceuticals News and Research

First Edition: May 6, 2014

Akorn’s consolidated revenue increases $90.6M to 23% in first quarter 2014

Bayer to purchase consumer care business of Merck & Co, signs co-development deal for sGC modulators

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Macrogenics, CMC Biologics sign agreement to develop oncology product candidate

Debiopharm signs new license and research agreement with Yale University

Kinex receives FDA allowance for Oratecan anti-cancer drug irinotecan with enhanced oral absorption

Attorney of Colson Hicks Eidson files wrongful death complaint on behalf of passenger killed on Macarthur Causeway

Teva's SYNRIBO for injection receives FDA approval for home administration

FDA approves Alexion’s Soliris drug for treatment of atypical hemolytic uremic syndrome

BeiGene receives $5M from Merck to develop BGB-283 BRAF inhibitor

ERYTECH Pharma gets authorization to initiate Phase II study in pancreatic cancer

Compounds in soy sauce can be 70 times more potent than first-line HIV drug Tenofovir

Viewpoints: Learning from enrollment numbers; health costs soaring; value of vaccinations

Researchers analyze living cells quickly and accurately using Raman spectroscopy

Cigna profits are up but costs from early marketplace customers also higher than expected

Trends, opportunities and threats in the life science industry: an interview with Bob Coughlin, CEO, MassBio

Cambrex sales decrease by 11.2% in first quarter 2014

Ruthigen files IND Application to FDA for lead drug candidate RUT58-60

Isis Pharmaceuticals reports final data from ISIS-APOCIIIRx Phase 2 study in patients with FCS

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence